CLOUDBREAK THERAPEUTICS LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding, Subsidiary
- Established
- 2015-09-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
6
Active:0
Completed:5
Trial Phases
3 Phases
Phase 1:1
Phase 2:4
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (66.7%)Phase 1
1 (16.7%)Phase 3
1 (16.7%)A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Cloudbreak Therapeutics, LLC
- Target Recruit Count
- 600
- Registration Number
- NCT05456425
- Locations
- 🇺🇸
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Walman Eye Center, Sun City, Arizona, United States
🇺🇸Bakersfield Eye Institute, Bakersfield, California, United States
Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop
Phase 1
Completed
- Conditions
- Myopia, Progressive
- Interventions
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Cloudbreak Therapeutics, LLC
- Target Recruit Count
- 84
- Registration Number
- NCT05372991
- Locations
- 🇦🇺
USC, Brisbane, Australia
Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Cloudbreak Therapeutics, LLC
- Target Recruit Count
- 95
- Registration Number
- NCT05261386
- Locations
- 🇺🇸
David Research Wirta, Newport Beach, California, United States
Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Cloudbreak Therapeutics, LLC
- Target Recruit Count
- 92
- Registration Number
- NCT04884243
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Cloudbreak Therapeutics, LLC
- Target Recruit Count
- 88
- Registration Number
- NCT04884256
- Locations
- 🇺🇸
Global Research Management, Glendale, California, United States
- Prev
- 1
- 2
- Next
News
No news found